Unicycive Therapeutics, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Shalabh Gupta, M.D. (CEO) and John Townsend (CFO) certified the Form 10-Q for the period ended June 30, 2026, filed August 12, 2026. Both officers affirmed that the report contains no untrue material statements, that financial statements fairly present the company's condition and operations, and that disclosure controls and internal controls over financial reporting are effective. No significant deficiencies, material weaknesses, or fraud were disclosed.
Why this rating
Routine Sarbanes-Oxley certifications are standard quarterly filings. No operational changes, financial data, counterparties, or material developments disclosed here.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.